8-K: Karyopharm Therapeutics Faces Nasdaq Delisting Threat After Share Price Falls Below $1.00

Karyopharm Therapeutics has received a notice from Nasdaq that its stock price has fallen below the minimum $1.00 threshold, potentially leading to delisting.

Summary

• Karyopharm Therapeutics received a deficiency letter from Nasdaq on September 16, 2024, because its stock price has been below $1.00 for 32 consecutive business days.
• This violates Nasdaq's minimum bid price rule for continued listing on the Global Select Market.
• Karyopharm has 180 days, until March 17, 2025, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
• If compliance is not achieved, Karyopharm may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market, provided it meets other listing requirements.
• To transfer to the Nasdaq Capital Market, Karyopharm would need to pay an application fee and notify Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
• If Karyopharm fails to regain compliance, Nasdaq may delist the stock, which the company could appeal.
• There is no guarantee that Karyopharm will be able to regain compliance with the bid price rule.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The potential need for a reverse stock split also adds to the negative outlook.

Positives

• Karyopharm has been granted an initial 180-day period to regain compliance with Nasdaq's minimum bid price rule.
• The company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• Karyopharm has the option to appeal a delisting determination to a Nasdaq Listing Qualifications Panel.

Negatives

• Karyopharm's stock price has fallen below the minimum $1.00 threshold for 32 consecutive business days.
• The company faces the risk of delisting from the Nasdaq Global Select Market if it does not regain compliance.
• There is no guarantee that Karyopharm will be able to regain compliance with the bid price rule.

Risks

• The company faces the risk of delisting from the Nasdaq Global Select Market if it does not regain compliance with the minimum bid price rule.
• There is no guarantee that Karyopharm will be able to regain compliance with the bid price rule.
• A reverse stock split may be necessary to regain compliance, which could negatively impact shareholders.
• The company may not be eligible for an additional compliance period if it does not meet the requirements for transferring to the Nasdaq Capital Market.

Future Outlook

Karyopharm intends to monitor its stock price and consider options to regain compliance, including a potential reverse stock split, but there is no assurance of success.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include seeking to effect a reverse stock split.

Industry Context

This announcement reflects the challenges faced by biotech companies with volatile stock prices, particularly those that are not yet profitable. Delisting notices are not uncommon in the sector, and companies often need to take measures such as reverse stock splits to maintain their listing.

Comparison to Industry Standards

• Many biotech companies with promising but not yet profitable pipelines face similar challenges with maintaining their stock price above the minimum listing requirements.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting threats in the past, highlighting the volatility in the biotech sector.
• Reverse stock splits are a common strategy used by companies in this situation, but they can be viewed negatively by investors as they reduce the number of shares outstanding and can signal financial distress.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Karyopharm will monitor its stock price.
• Karyopharm may consider a reverse stock split.
• Karyopharm may need to transfer to the Nasdaq Capital Market if it does not regain compliance by March 17, 2025.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, reverse stock split, Karyopharm Therapeutics, KPTI, stock price